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Abstract Short non-lethal ischemic episodes adminis-
tered to hearts prior to (ischemic preconditioning, IPC)
or directly after (ischemic postconditioning, IPost)
ischemic events facilitate myocardial protection. Trans-
ferring coronary efﬂuent collected during IPC treatment
to un-preconditioned recipient hearts protects from lethal
ischemic insults. We propose that coronary IPC efﬂuent
contains hydrophobic cytoprotective mediators acting via
PI3K/Akt-dependent pro-survival signaling at ischemic
reperfusion. Ex vivo rat hearts were subjected to 30 min
of regional ischemia and 120 min of reperfusion. IPC
efﬂuent administered for 10 min prior to index ischemia
attenuated infarct size by C55% versus control hearts
(P\0.05). Efﬂuent administration for 10 min at imme-
diate reperfusion (reperfusion therapy) or as a mimetic of
pharmacological postconditioning (remote postcondition-
ing, RIPost) signiﬁcantly reduced infarct size compared
to control (P\0.05). The IPC efﬂuent signiﬁcantly
increased Akt phosphorylation in un-preconditioned
hearts when administered before ischemia or at reperfu-
sion, while pharmacological inhibition of PI3K/Akt-sig-
naling at reperfusion completely abrogated the
cardioprotection offered by efﬂuent administration.
Fractionation of coronary IPC efﬂuent revealed that
cytoprotective humoral mediator(s) released during the
conditioning phase were of hydrophobic nature as all
hydrophobic fractions with molecules under 30 kDa
signiﬁcantly reduced infarct size versus the control and
hydrophilic fraction-treated hearts (P\0.05). The total
hydrophobic efﬂuent fraction signiﬁcantly reduced infarct
size independently of temporal administration (before
ischemia, at reperfusion or as remote postconditioning).
Inconclusion,theIPCefﬂuentretainsstrongcardioprotective
properties, containing hydrophobic mediator(s)\30 kDa
offering cytoprotection via PI3K/Akt-dependent signaling at
ischemic reperfusion.
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Introduction
Impaired coronary circulation caused by a myocardial
ischemic episode will lead to compromised hemodynamic
function and ultimately cell death. Rapid restoration of
coronary blood ﬂow to the infarct-related coronary artery
by thrombolysis or primary coronary angioplasty is
effective interventions for limiting myocardial infarct size
and improving clinical outcomes [20, 39]. Although early
reperfusion is essential to limit infarct size, it may para-
doxically induce cell death (lethal reperfusion injury) [2].
Two ways of protecting the heart against reperfusion-
induced injury are ischemic preconditioning (IPC) [22] and
ischemic postconditioning (IPost) [40], applying transient
non-lethal episodes of myocardial ischemia and reperfu-
sion either before or after the index ischemic event,
respectively. Another strategy for achieving cardioprotec-
tion is remote ischemic preconditioning (RIPC), whereby
brief ischemia in one distant region or organ protects the
heart from a sustained episode of ischemia [26]. Remote
IPost (RIPost) is a more clinically relevant cardioprotec-
tive strategy, and has been shown to be effective in
experimental studies when the remote ischemic
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ischemia [15].
There is strong evidence that one or more factors
released in response to brief episodes of ischemia during
IPC can interact with receptors, locally or at a distance,
triggering a cytoprotective response. Dickson et al. [6]
found that IPC-induced cardioprotection could be trans-
ferred between individuals by transfusion of whole blood
from preconditioned to non-preconditioned rabbits and
that efﬂuent from preconditioned isolated ex vivo rabbit
hearts offered protection to non-preconditioned hearts [5].
Furthermore, Serejo et al. [28] recently showed that car-
dioprotective factors released into coronary IPC efﬂuent
from ex vivo rat hearts are thermolabile hydrophobic
substances with molecular weights higher than 3.5 kDa
offering cytoprotection via PKC activation in the recipient
heart. In addition, Lang et al. [17] suggested that media-
tor(s) released during IPC in rat hearts are smaller than
8 kDa.
IPC and IPost reduce infarct size when studied in a
wide variety of experimental models including rat, rabbit,
dog, pig and primates by sharing similar mechanisms and
exerting most of their cytoprotection at reperfusion [9, 12,
26, 37]. IPC activates PI3-kinase which facilitates phos-
phorylation and activation of the protein kinase Akt
through its mediator PDK-1 [1]. Akt is part of the
reperfusion injury salvage kinases (RISK) that confer
cardioprotection when activated at reperfusion [9]. IPost
activates similar signaling pathways to IPC [9] and is
thereby also dependent on RISK activation to exert its
protection [35], although the involvement of RISK has
lately been proven to be species dependent [27, 30]. The
underlying mechanism of RIPC and RIPost remains
unclear, but many of the signaling pathways underlying
myocardial preconditioning and postconditioning have
been implicated in RIPC [11].
Numerous studies have focused on characterizing the
signaling mechanisms involved in IPC. However, the pre-
cise adaptive response triggered by agents released during
the short reperfusion episodes of IPC remains unresolved.
Identiﬁcation of such mediators would be of great impor-
tance for the development of pharmacological therapies to
enhance myocardial tolerance to ischemia–reperfusion-
induced stress in patients with acute myocardial infarction
(AMI) [38]. The aims of this study were therefore to (1)
investigate the protective capabilities of the IPC efﬂuent
when delivered at ischemic reperfusion and its potential to
induce remote postconditioning (RIPost); (2) determine if
coronary IPC efﬂuent mediates its protection through a
PI3K/Akt-dependent cytoprotective signaling pathway; (3)
characterize the protective mediator(s) by fractionation of
efﬂuent based on different properties such as hydropho-
bicity and size.
Methods
Langendorff perfusion procedure
All experiments were approved by the Norwegian State
Commission for Laboratory Animals, and carried out in
accordance with the European Communities Council
Directive of 1986 (86/609/EEC).
Male Wistar rats (250–350 g, n = 183) fed a standard
diet were heparinized (200 IU) and anesthetized with
sodium pentobarbital (50 mg/kg) i.p. The hearts were
excised, placed in ice-cold Krebs–Heinseleit buffer (KHB)
and rapidly mounted onto a Langendorff perfusion system.
KHB (pH 7.4, oxygenated with 95% O2/5% CO2) con-
tained in mM: 118 NaCl, 4.7 KCl, 1.8 CaCl2, 1.2 KH2PO4,
1.2 MgSO4, 25.2 NaHCO3, 11.0 glucose. Perfusion pres-
sure was maintained at 100 cmH2O, and the myocardial
temperature kept at 37.5C. A water-ﬁlled latex balloon,
connected to a hydrostatic pressure transducer (SP844,
Memscap, Norway) and coupled to a high performance
data acquisition system (PowerLab 8/30, Chart Pro soft-
ware-MLS250, Australia), was inserted into the left ven-
tricle and inﬂated to set an end-diastolic pressure of
5–10 mmHg. Coronary ﬂow (CF) was measured by timed
collection of efﬂuent over 1 min. A 3-0 silk suture was
passed around the main branch of the left coronary artery,
and threaded through a small vinyl tube to form a snare.
Regional ischemia (RI) was achieved by pulling the snare,
and conﬁrmed by a substantial fall in left ventricular
developed pressure (LVDP) and CF.
Experimental protocols
The experimental protocols are shown in Fig. 1. Baseline
values for functional parameters were obtained after
10 min of stabilization. All hearts were subjected to the
ischemia/reperfusion (I/R) protocol consisting of 30 min of
regional ischemia (RI = index ischemia) and 120 min
of reperfusion. The IPC protocol consisted of 39 5 min of
global ischemia (GI) with 5 min intermittent reperfusions
prior to RI. Coronary IPC efﬂuent (*150 ml) was col-
lected during the intermittent reperfusion periods. Fresh
efﬂuent was used for each experiment. Since studies show
that coronary efﬂuent from non-preconditioned hearts does
not inﬂuence the infarct size when administered to reci-
pient hearts [28], we did not repeat these experiments in
this study.
Initially, effects of coronary IPC efﬂuent were studied
during two temporal distinct administration periods, before
and after index ischemia (Fig. 1a). IPC efﬂuent was
administered 10 min prior to index ischemia (EffPre) and for
10 min at reperfusion (EffRep). Subsequently, IPC efﬂuent
was administered to simulate ischemic postconditioning
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123(RIPost) by perfusing the coronary efﬂuent for 39 30 s at
early reperfusion (EffPost). The ischemic postconditioning
(IPost) protocol consisted of 39 30 s GI intermitted by 30 s
reperfusion periods. Furthermore, to explore if the cardio-
protective properties mediated by the coronary IPC efﬂuent
were dependent on PI3K/Akt-dependent signaling at
reperfusion, the PI3K-inhibitor Wortmannin (WI; 1 lM)
(Tocris Bioscience, UK) and the Akt-inhibitor SH-6
(10 lM) (Enzo Life Sciences, New York, USA) were
administered for 10 min at ischemic reperfusion (EffPre ?
WI/SH-6 and EffRep ? WI/SH-6 and EffPost ? WI;
Fig. 1a). Since WI attenuated the cytoprotective effect of
the efﬂuent administered as a RIPost stimulus, and further
that SH-6 abolished the IPC efﬂuent-induced cardiopro-
tection at reperfusion, we did not include experiments with
efﬂuent RIPost and the SH-6 inhibitor.
To further delineate the properties of putative cytopro-
tective mediator(s) released into collected IPC efﬂuent,
another set of experiments was performed (Fig. 1b).
Firstly, efﬂuent was separated into hydrophilic and
hydrophobic fractions and administered either prior to
ischemia (HPhilPre and HPhobPre) or at reperfusion
(HPhobRep and HPhobPost). The hydrophobic efﬂuent was
further fractionated using spin columns containing cut-off
ﬁlters of either 10 or 30 kDa, resulting in four different
fractions that were administered to recipient hearts either
prior to ischemia (HPhobPre\10 and HPhobPre[10) or at
reperfusion (HPhobRep\30 and HPhobRep[30).
Fractionation of IPC efﬂuent
Coronary efﬂuent from isolated ex vivo Langendorff per-
fused rat hearts exposed to IPC was collected during the
intermittent reperfusion periods. The efﬂuent was taken
through a series of preparation steps in order to purify
putative mediators of IPC-mediated cardioprotection. C18
solid phase extraction cartridges (Waters Corp., USA) were
conditioned with 6 ml 100% acetonitrile (ACN) followed
by equilibration with 6 ml of ddH2O. Thereafter, IPC
efﬂuent was applied to the cartridge at a ﬂow rate of 1 ml/
min. Following this, the cartridge was washed with 10 ml
water to elute unbound hydrophilic compounds (hydro-
philic fraction). Hydrophobic proteins were eluted with
6 ml of 60% ACN. To remove the organic phase, eluted
sample was evaporated under a stream of nitrogen. The
hydrophobic eluted fraction was then either re-suspended
in KHB for perfusion or re-suspended in ddH2O and sub-
jected to spin columns with either 10 or 30 kDa cut-off
ﬁlter (Sartorius Stedim Biotech, France) and thereafter
diluted in KHB (total volume of 150 ml KHB) before
perfusion. All fractions were perfused to untreated reci-
pient hearts for 10 min either prior to index ischemia
(HPhilPre or HPhobPre) or at reperfusion (HPhobRep or
HPhobPost) (Fig. 1b).
Determination of infarct size
At the end of each experiment, the silk suture was securely
tightened and a 0.2% (w/v) Evans Blue solution (Sigma
Chemicals Co., USA) infused to visualize the risk zone.
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Fig. 1 Experimental protocols. All groups were subjected to 30 min
of regional ischemia (RI) followed by 120 min of reperfusion. Hearts
receiving no other treatments constitute the control group (Ctr). a The
IPC group was exposed to 39 5 min global ischemia (GI), with 5 min
intermittent reperfusion periods prior to RI. To test the temporal
cytoprotective efﬁcacy of IPC efﬂuent in recipient hearts, freshly
collected efﬂuent was administered for 10 min prior to RI (EffPre)o r
for 10 min at onset of ischemic reperfusion (EffRep). Furthermore, to
mimic ischemic postconditioning, the IPC efﬂuent was administered
for 39 30 s with 30 s intermittent KHB perfusion at immediate
reperfusion (EffPost). Ischemic postconditioning (IPost) was achieved
by 39 30 s of global ischemia (GI) at early ischemic reperfusion. The
PI3K-inhibitor WI (1 lM) and the Akt-inhibitor SH-6 (10 lM) were
administered for 10 min at immediate onset of ischemic reperfusion
in conjunction with 10 min of pre- or post-ischemic treatment with
IPC efﬂuent (EffPre ? WI/SH-6, EffRep ? WI/SH-6 or EffPost ? WI).
b The IPC efﬂuent was fractionated in respect to charge and size.
Efﬂuent collected during IPC was ﬁrst separated into a hydrophilic
(HPhil) and a hydrophobic (HPhob) fraction. All total efﬂuent
fractions were administered for either 10 min prior to ischemia
(HPhilPre and HPhobPre) or for 10 min at reperfusion (HPhobRep and
HPhobPost). The hydrophobic fraction was further fractionated by a 10
or 30 kDa size ﬁlter resulting in four hydrophobic fractions with
molecules below 10/30 kDa (HPhobPre\10 and HPhobRep\30) or
above 10/30 kDa (HPhobPre[10 and HPhobRep[30). Arrows
indicate time points for tissue sampling. Solid lines KH buffer
perfusion
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123Hearts were thereafter frozen at -20C before being cut
into 2-mm thick slices parallel to the atrioventricular
groove and stained with 1% triphenyl-tetrazolium-chloride
(TTC, Sigma Chemicals Co, USA) in phosphate buffer (pH
7.4) for 20 min at 37C. The slices were then immersed in
4% (v/v) formalin to enhance contrast of the stain, before
being placed between two glass plates and digitalized. Area
at risk (AAR, i.e. area not stained by Evans Blue), live cells
(TTC positive, i.e. red) and infarcted area (TTC negative)
were determined in a blinded fashion using a computerized
planimetry program (Planimetry
? v2.0; Erik Traasdahl,
ENK, Norway). Infarct size is presented as the ratio
between the infarcted area and AAR in percent. There were
no signiﬁcant differences between the different treatment
groups in the relative size of the AAR (volume of area at
risk/volume of left ventricle) (Table 1).
Immunoblot analysis
Levels of Akt (total-Akt, Santa Cruz Biotechnology, Cal-
ifornia, USA) and its phosphorylation at Ser
473 (p-Akt, Cell
Signal, Massachusetts, USA) were determined by western
blotting. Heart tissue was harvested at stabilization (control
baseline, CB), at the end of IPC protocol or at 15 min of
reperfusion (time points indicated by arrow in Fig. 1a).
Furthermore, in order to explore the potential of pre-
ischemic efﬂuent administrations ability to modulate Akt
phosphorylation at reperfusion, a separate group for WB
only were administered efﬂuent for 10 min prior to index
ischemia and the tissue harvested after these hearts had
been reperfused for 15 min (EffPre?Rep). At the end of the
experiment, AAR of the left ventricle was excised and snap
frozen in liquid nitrogen. Homogenization of cardiac tis-
sue, protein quantiﬁcation, sample preparation (40 lg per
lane) and electrophoresis were performed as previously
described [14]. Densitometric analysis was performed
using Quantity One software (Bio-Rad, CA, USA) and
phosphorylation of Akt was expressed as the ratio between
p-Akt and total-Akt. Results normalized against baseline
hearts, CB. GADPH was used as loading control (Santa
Cruz Biotechnology, California, USA).
Statistical analysis
Values are presented as mean ± standard error of the mean
(SEM). Infarct sizes and AAR were tested for group dif-
ferences by one-way analysis of variance (ANOVA)
combined with Fisher’s post hoc test. Comparisons of
LVDP, HR and CF were performed with ANOVA com-
bined with Bonferroni post hoc test. To test for immunoblot
differences, Student’s t test for independent samples was
used. For all tests, P\0.05 was considered statistically
signiﬁcant.
Results
IPC efﬂuent induces remote postconditioning
by reducing infarct size when administered
at reperfusion
Administration of IPC efﬂuent from the onset of reperfu-
sion signiﬁcantly reduced infarct size in un-preconditioned
recipient hearts compared to controls (EffRep:2 5± 4% vs.
Ctr: 54 ± 5%, P\0.05; Fig. 2). Furthermore, the infarct
size reduction was comparable to that of hearts subjected to
ischemic preconditioning (IPC) or treated with IPC efﬂuent
prior to index ischemia (EffPre) (IPC: 21 ± 2%, EffPre:
24 ± 6% vs. EffRep:2 5± 4%, ns; Fig. 2).
Table 1 Ratio of volume of area at risk (AAR) and left ventricle
(LV) by Evans Blue staining
Group AAR/LV
Ctr 0.43 ± 0.03
Ctr ? WI 0.53 ± 0.06
Ctr ? SH-6 0.41 ± 0.04
IPC 0.46 ± 0.02
EffPre 0.50 ± 0.03
EffPre ? SH-6 0.48 ± 0.04
EffPre ? WI 0.34 ± 0.03
EffRep 0.39 ± 0.03
EffRep ? SH-6 0.36 ± 0.03
EffRep ? WI 0.47 ± 0.02
IPost 0.52 ± 0.03
EffPost 0.46 ± 0.03
EffPost ? WI 0.43 ± 0.05
HPhilPre 0.42 ± 0.03
HPhobPre 0.43 ± 0.09
HPhobRep 0.39 ± 0.05
HPhobPost 0.36 ± 0.04
HPhobPre\10 0.43 ± 0.03
HPhobPre[10 0.45 ± 0.02
HPhobRep\30 0.45 ± 0.03
HPhobRep[30 0.46 ± 0.01
Values represent mean ± SEM
Ctr ischemia–reperfusion controls; IPC ischemic preconditioning, 39
5 min; EffPre/HPhobPre 10 min efﬂuent administration prior to
ischemia; EffRep/HPhobRep 10 min efﬂuent administration at reper-
fusion; IPost ischemic postconditioning, 39 30 s; EffPost/HPhobPost
postconditioning mimetic, 39 30 s; WI 10 min Wortmannin (1 lM);
SH-6 10 min SH-6 (10 lM) at reperfusion; HPhil efﬂuent not bound
to C18 column; HPhob total efﬂuent eluted from C18 column;\or
[10 or 30 kDa total hydrophobic fraction further separated by size
exclusion column
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123In addition, mimicking pharmacological postcondition-
ing by administering IPC efﬂuent to recipient hearts for 39
30 s at onset of reperfusion (RIPost) signiﬁcantly reduced
infarct size as compared to control hearts (EffPost:3 5± 3%
vs.Ctr:54 ± 5%,P\0.05;Fig. 3).Therewasnostatistical
difference in infarct size comparing the IPost and EffPost
groups (IPost: 30 ± 5% vs. EffPost:3 5± 3%, ns; Fig. 3).
Lastly, comparing the infarct sizes in all IPC efﬂuent-
treated groups, it is apparent that the efﬂuent confers
similar degree of cytoprotection independent of whether
treatment was administered before or after the index
ischemic insult (EffPre:2 4± 6%, EffRep:2 5± 4% and
EffPost:3 5± 3%, ns; Figs. 2, 3). Furthermore, coronary
IPC efﬂuent conveys cardioprotection comparable to IPC
hearts, revealing that the putative cytoprotective media-
tor(s) could lead to a very promising therapeutic strategy
for patients being revascularized after AMI.
The cytoprotection offered by IPC efﬂuent
at reperfusion is mediated by PI3K/Akt-dependent
cell-survival signaling in recipient heart
IPCisknowntoactivatethe pro-survivalkinaseAktdirectly
after the IPC protocol [34]. Interestingly, administration of
IPC efﬂuent prior to index ischemia caused a signiﬁcant
increaseinAktphosphorylationcomparedtoheartsexposed
to IPC treatment only (EffPre: 5.2 ± 0.2 AU vs. IPC:
2.0 ± 0.2 AU,P\0.05;Fig. 4a,b),indicatinganincreased
potentialofthe IPC efﬂuent toactivatethe pro-survival Akt-
signaling as compared to the IPC stimulus itself. Further-
more, administration of IPC efﬂuent at reperfusion elevated
the Akt-phosphorylation compared to I/R control hearts
(EffRep: 7.2 ± 0.2 AU vs. CtrRep: 2.0 ± 0.5 AU, P\0.05;
Fig. 4c, d). Treatment with pre-ischemic IPC efﬂuent and
analysis of Akt phosphorylation at reperfusion (EffPre?Rep)
also increased phosphorylation status of Akt as compared to
the I/R control group (EffPre?Rep:4 . 2± 0.6 AU vs. CtrRep:
2.0 ± 0.5 AU, P\0.05; Fig. 4c, d).
Total Akt or GADPH did not alter during the experi-
ments (Fig. 4a, c), implying that increased relative phos-
phorylation is a result of changes in Akt phosphorylation
and not alterations in the total kinase level or unequal
loading. Exploring the phosphorylation status of STAT-3, a
member of the Survivor Activating Factor Enhancement
(SAFE) pathway [18], we found no regulation (results not
shown).
Hausenloy et al. [9] have previously shown that Akt
phosphorylation at reperfusion is essential for IPC-induced
protection, since inhibition of this kinase during early
reperfusion abrogated the IPC-mediated reduction in
infarct size. Therefore, to elucidate whether IPC efﬂuent
exerts its cardioprotective effect through an PI3K/Akt-
dependent signaling pathway activated at reperfusion,
hearts were administered fresh IPC efﬂuent for 10 min
either prior to index ischemia (EffPre) or at reperfusion
(EffRep or EffPost), and co-administered the PI3K-inhibitor
WI or the Akt-inhibitor SH-6 for 10 min at reperfusion (see
experimental protocol Fig. 1). The protective effect of IPC
efﬂuent was completely abolished by co-administering WI
or SH-6 at reperfusion compared to the EffPre group
(EffPre ? WI: 51 ± 7%, EffPre ? SH-6: 60 ± 4% vs.
EffPre:2 4± 6%, P\0.05; Fig. 5) and the EffRep group
(EffRep ? WI: 56 ± 12%, EffRep ? SH-6: 54 ± 8% vs.
EffRep:2 5 ± 4%, P\0.05; Fig. 5) and EffPost group
(EffPost ? WI: 50 ± 11% vs. EffPost;3 5± 3%, P\0.05)
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Fig. 2 The temporal effect of treatment with IPC efﬂuent on
myocardial infarct size. Infarct size is expressed as percentage of
the region at risk of infarction (area at risk). Efﬂuent from
preconditioned donor hearts (IPC) administered either 10 min prior
to index ischemia (EffPre) or for 10 min at ischemic-reperfusion
(EffRep) signiﬁcantly reduced infarct size in non-preconditioned
recipient hearts as compared to controls (Ctr). Bars represent
mean ± SEM. N C 7 in each group. *P\0.05 versus Ctr group
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Fig. 3 The effect of administering IPC efﬂuent as a mimetic of
ischemic postconditioning (RIPost) on myocardial infarct size.
Treatment of recipient hearts with IPC efﬂuent for 39 30 s at
ischemic reperfusion (EffPost) reduced infarct size to the same extent
as ischemic postconditioning (IPost), and both groups had signif-
icantly reduced infarct size as compared to the control group (Ctr).
Bars represent mean ± SEM. N C 7 in each group. *P\0.05 versus
Ctr
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123(data not shown). SH-6 is a phosphatidylinositol (PI) analog
that inhibits Akt without affecting the activity of its
upstream kinase PDK-1 [16], and has also been shown to
prevent phosphorylation of Akt at Ser
473 [4, 32]. The
inhibitors themselves had no effect on infarct size (WI:
54 ± 8%, SH-6: 52 ± 3% vs. Ctr: 54 ± 5%, ns). Further-
more, both WI and SH-6 signiﬁcantly reduced Akt phos-
phorylation in IPC efﬂuent-treated hearts (EffRep ? WI:
0.7 ± 0.1 AU, EffRep ? SH-6: 2.8 ± 0.2 AU vs. EffRep:
7.2 ± 0.2 AU, P\0.05; Fig. 4c, d).
FunctionalparametersareshowninTables 2and3.There
werenomajorgroupdifferencesconcerningbaselinevalues,
values at the start of RI or at reperfusion (Tables 2, 3).
Cardioprotective potency of fractionated IPC efﬂuent
To further characterize potential humoral factor(s), the
coronary IPC efﬂuent was separated into hydrophilic and
hydrophobic fractions, and the hydrophobic fraction was
further divided based on particulate size ([ or \10 or
30 kDa). The total hydrophobic efﬂuent fraction adminis-
tered for 10 min before hearts were subjected to 30 min of
regional ischemia (HPhobPre) resulted in a signiﬁcantly
reduced infarct size as compared to hydrophilic fraction-
treated hearts and controls (HPhilPre:5 9 ± 4%, Ctr:
54 ± 5% vs. HPhobPre:2 8± 5%, P\0.05; Fig. 6). Fur-
thermore, administration of the total hydrophobic efﬂuent
fraction at ischemic reperfusion also resulted in signiﬁ-
cantly reduced infarct size as compared to controls
(HPhobRep:2 9 ± 3%, HPhobPost:2 2 ± 4% vs. Ctr:
54 ± 5%, P\0.05; Fig. 6). We further fractionated the
hydrophobic IPC efﬂuent into four fractions with particu-
late size[or\10 or 30 kDa. All fractions below 30 kDa
afforded cardioprotection as compared to control hearts
(HPhobPre\10: 27 ± 4%, HPhobPre[10: 37 ± 5%,
HPhobRep\30: 36 ± 6% vs. Ctr: 54 ± 5%, P\0.05;
Fig. 6). However, the cytoprotective mediator in the IPC
efﬂuent appears to be of a size less than 30 kDa as the
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Fig. 4 Phosphorylation status of myocardial Akt in recipient hearts
exposed to treatment with IPC efﬂuent. a Representative immuno-
blots of Akt phosphorylation (Ser
473) showing the effects of treatment
with IPC efﬂuent (EffPre) in recipient hearts (tissue harvested at end of
treatment), as compared to hearts exposed to the standard IPC
protocol (IPC) and baseline hearts (CB). c Representative immuno-
blots of Akt phosphorylation (Ser
473) in pre-ischemic IPC efﬂuent-
treated hearts that was also reperfused for 15 min (EffPre?Rep) and
reperfusion treatment with IPC efﬂuent (EffRep) in recipient hearts as
compared to ischemic reperfused control hearts (CtrRep) (tissues
harvested at 15 min of reperfusion). Administering the PI3K-inhibitor
WI (1 lM) and the Akt-inhibitor SH-6 (10 lM) for 10 min at
reperfusion abrogated Akt phosphorylation in IPC efﬂuent-treated
hearts. Total Akt and GADPH indicates equal loading. b, d Densito-
metric analysis of total and phosphorylated Akt immunoblots
expressed in arbitrary units (AU). p-Akt expressed as a ratio of total
Akt with CB = 1. Bars represent mean ± SEM. N C 3 in each group.
*P\0.05 versus CB,
P\0.05 versus IPC,
§P\0.05 versus
EffPre?Rep,
¤P\0.05 versus EffRep,
#P\0.05 versus CtrRep
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123group with particulate fraction above this size failed to
offer any cardioprotection (HPhobRep[30: 52 ± 4% vs.
Ctr: 54 ± 5%, ns).
Discussion
To summarize, our data demonstrate that collected coro-
nary IPC efﬂuent contains humoral factor(s) of a hydro-
phobic character\30 kDa in size that offers strong
cytoprotective properties, signiﬁcantly reducing infarct size
when administered at early ischemic reperfusion in reci-
pient rat hearts, either given as a reperfusion therapy or as
pharmacological mimetic of ischemic postconditioning
(remote IPost). Moreover, these data suggest that this
cardioprotection is partly mediated via PI3K/Akt-depen-
dent cell-survival signaling at ischemic reperfusion.
Our results are in agreement with experiments per-
formed by Serejo et al. [28] and Dickson et al. [5] in the ex
vivo rat and rabbit heart, respectively. These studies
demonstrate that coronary efﬂuent from donor hearts sub-
jected to IPC confers cardioprotection in isolated buffer-
perfused ex vivo recipient hearts administered prior to
index ischemia. However, coronary reperfusion is the only
means of limiting infarct size, provided that it occurs early
after coronary occlusion, but may paradoxically directly
result in tissue injury (lethal reperfusion injury). In order to
explore if collected IPC coronary efﬂuent could reduce
lethal reperfusion-induced injury, we administered IPC
efﬂuent for 10 min at immediate reperfusion. Our results
conﬁrm that IPC efﬂuent limits reperfusion-induced injury
by proving able to offer cytoprotection similar to pre-
ischemic treatment even when administered as reperfusion
therapy (Fig. 2). In order to further evaluate the temporal
requirements of the IPC efﬂuent, it was administered as a
postconditioning stimulant at early reperfusion (experi-
mental protocol, Fig. 1), drastically reducing the total
treatment time and volume. Nevertheless, exposing the
recipient hearts to *85% less efﬂuent over a shorter time
period still offered substantial cardioprotection in un-pre-
conditioned hearts, also validating the phenomena of
remote postconditioning (RIPost).
The study by Serejo et al. [28] indicated that the pro-
tective effect afforded by IPC efﬂuent disappeared when
heated or left in RT for 24 h, while addition of protease
inhibitors prevented this time-dependent break down and
efﬂuent puriﬁcation by reverse phase chromatography
suggested that the cardioprotective factor(s) could be of a
hydrophobic ‘‘protein nature’’. Our results conﬁrm these
ﬁndings as administration of total isolated hydrophobic
fraction prior to index ischemia or at reperfusion, as
reperfusion therapy or RIPost treatment, reduced infarct
size by 35–40% compared to control and hydrophilic
fraction-treated group. Further fractionation of the total
hydrophobic efﬂuent into low and high molecular weight
fractions, with either a 10 or 30 kDa cut-off, revealed that
both 10 kDa fractions, but only the low weight fractions of
30 kDa cut-off, retained the ability to offer cardioprotec-
tion comparable to the cytoprotection afforded by the total
hydrophobic faction (Fig. 6). Thus, we propose that the
factor(s) responsible for the protective capabilities have a
size either under or close to 30 kDa (depending on the
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Fig. 5 The effect of inhibiting PI3K and Akt upon reperfusion in IPC
efﬂuent-treated recipient hearts. When administering the PI3K-
inhibitor WI and the Akt-inhibitor SH-6 at the onset of reperfusion
in IPC efﬂuent pre-ischemic (EffPre) or post-ischemic (EffRep and
EffPost) treated hearts, the cardioprotective effect of the efﬂuent was
completely abolished. Ctr control; EffPre 10 min efﬂuent
administration prior to RI; EffRep 10 min efﬂuent administration after
RI; EffPost efﬂuent administration 39 30 s at start of reperfusion; WI
10 min Wortmannin (1 lM) at reperfusion; SH-6 10 min SH-6
(10 lM) at reperfusion. Bars represent mean ± SEM. N C 6 in each
group. *P\0.05 versus Ctr
Basic Res Cardiol (2011) 106:135–145 141
123efﬁciency of the columns used). Since both 10 kDa frac-
tions were protective, this suggests that the efﬂuent either
contains more than one factor with protective capabilities,
with at least one of them being of a smaller and one of a
larger size than the size of the ﬁlter used (10 kDa), or that
the factor(s) is of a size close to the columns 10 kDa cut-
off limit, causing it to be present in both fractions.
Adenosine, opioids and bradykinin are endogenously
released triggers of IPC that work in parallel, binding to
Table 2 Functional parameters recorded during the experimental
protocol investigating the temporal effects of administering the IPC
efﬂuent to un-preconditioned recipient hearts
Group 10 min stab 5 min RI 30 min rep 120 min rep
LVDP (mmHg)
Ctr 155 ± 22 87 ± 8
# 109 ± 12 78 ± 8
#
Ctr ? WI 160 ± 12 73 ± 11
# 71 ± 96 7 ± 6
#
Ctr ? SH-6 149 ± 17 78 ± 13
# 112 ± 9
# 84 ± 10
#
IPC 160 ± 11 73 ± 7
# 98 ± 7
# 70 ± 5
#
EffPre 171 ± 21 73 ± 14
# 87 ± 2
# 67 ± 5
#
EffPre ? SH-6 177 ± 17 113 ± 11
# 68 ± 8
# 51 ± 3
#
EffPre ? WI 148 ± 12 73 ± 9
# 81 ± 7
# 66 ± 6
#
EffRep 177 ± 98 4 ± 14
# 104 ± 10
# 77 ± 9
#
EffRep ? SH-6 156 ± 8 103 ± 9
# 93 ± 7
# 74 ± 6
#
EffRep ? WI 162 ± 17 111 ± 18
# 97 ± 18
# 69 ± 13
#
IPost 150 ± 10 68 ± 11
# 78 ± 9
# 59 ± 7
#
EffPost 157 ± 19 80 ± 14
# 106 ± 96 1 ± 8
#
EffPost ? WI 156 ± 11 99 ± 15
# 94 ± 15
# 85 ± 10
#
CF (ml/min)
Ctr 13.4 ± 1.7 9.1 ± 1.3
# 9.1 ± 0.8
# 6.2 ± 0.7
#
Ctr ? WI 12.9 ± 0.6 7.3 ± 0.6
# 10.5 ± 0.8 7.3 ± 0.6
#
Ctr ? SH-6 12.8 ± 0.4 7.9 ± 0.4
# 6.2 ± 1.6
# 6.1 ± 1.1
#
IPC 14.2 ± 0.9 8.0 ± 0.7
# 12.1 ± 1.1 7.3 ± 0.9
#
EffPre 13.3 ± 0.5 6.9 ± 0.8
# 8.0 ± 0.5
# 6.5 ± 0.6
#
EffPre ? SH-6 17.2 ± 3.2 8.7 ± 1.2
# 6.8 ± 0.8
# 6.2 ± 1.1
#
EffPre ? WI 15.8 ± 1.5 7.8 ± 0.8
# 10.8 ± 1.0
# 7.1 ± 1.0
#
EffPre 13.6 ± 1.0 8.1 ± 1.0
# 10.2 ± 0.4
# 7.5 ± 0.4
#
EffPre ? SH-6 14.9 ± 0.9 8.9 ± 0.9
# 7.8 ± 0.6
# 6.5 ± 0.6
#
EffRep ? WI 15.6 ± 0.6 7.6 ± 1.1
# 9.3 ± 1.5
# 7.1 ± 1.4
#
IPost 12.3 ± 0.8 7.2 ± 0.5
# 8.2 ± 0.9
# 5.9 ± 0.3
#
EffPost 13.8 ± 0.7 8.4 ± 0.6
# 10.4 ± 0.7
# 7.6 ± 0.6
#
EffPost ? WI 14.1 ± 0.6 8.9 ± 0.8
# 11.4 ± 0.9 8.7 ± 0.4
#
HR (beats/min)
Ctr 328 ± 21 294 ± 34 268 ± 31 254 ± 17
Ctr ? WI 300 ± 12 288 ± 12 258 ± 43 293 ± 23
Ctr ? SH-6 318 ± 17 276 ± 16 299 ± 18 246 ± 15
IPC 295 ± 22 283 ± 17 270 ± 13 242 ± 9
EffPre 321 ± 12 278 ± 19 285 ± 15 270 ± 14
EffPre ? SH-6 294 ± 18 250 ± 11 236 ± 11 226 ± 29
EffPre ? WI 297 ± 13 298 ± 25 339 ± 23 289 ± 23
EffRep 275 ± 23 273 ± 15 276 ± 19 268 ± 14
EffRep ? SH-6 256 ± 17 238 ± 17 224 ± 17 236 ± 12
EffRep ? WI 277 ± 32 248 ± 30 261 ± 30 241 ± 28
IPost 298 ± 15 266 ± 13 261 ± 9 233 ± 6
EffPost 280 ± 7 230 ± 16 293 ± 15 239 ± 14
EffPost ? WI 316 ± 16 304 ± 24 301 ± 23 278 ± 33
Values represent mean ± SEM
Ctr ischemia–reperfusion controls; IPC ischemic preconditioning, 39
5 min; EffPre 10 min efﬂuent administration prior to ischemia; EffRep
10 min efﬂuent administration at reperfusion; IPost ischemic postcondi-
tioning, 39 30 s; EffPost efﬂuent postconditioning, 39 30 s; WI 10 min
Wortmannin (1 lM); SH-6 10 min SH-6 (10 lM) at reperfusion
# P\0.05 versus Stab
Table 3 Functional parameters recorded during the experimental
protocol investigating the effects of administering fractionated IPC
efﬂuent (charge and size) to un-preconditioned recipient hearts
Group 10 min stab 5 min RI 30 min rep 120 min rep
LVDP (mmHg)
Ctr 155 ± 22 87 ± 8
# 109 ± 12 78 ± 8
#
HPhilPre 153 ± 98 7 ± 8
# 96 ± 9
# 69 ± 9
#
HPhobPre 151 ± 68 9 ± 18
# 100 ± 5
# 87 ± 5
#
HPhobRep 168 ± 20 89 ± 8
# 90 ± 16 71 ± 11
#
HPhobPost 143 ± 87 8 ± 8
# 90 ± 5
# 73 ± 5
#
HPhobPre\10 143 ± 15 62 ± 9
# 101 ± 8
# 74 ± 7
#
HPhobPre[10 149 ± 13 81 ± 13
# 111 ± 98 3 ± 7
#
HPhobRep\30 173 ± 98 3 ± 8
# 107 ± 5
# 82 ± 5
#
HPhobRep[30 160 ± 15 100 ± 13
# 83 ± 6
# 64 ± 7
#
CF (ml/min)
Ctr 13.2 ± 1.4 8.8 ± 1.2
# 8.6 ± 0.8
# 5.8 ± 0.7
#
HPhilPre 13.6 ± 0.5 8.4 ± 0.8
# 10.2 ± 0.9 7.6 ± 0.8
#
HPhobPre 13.7 ± 0.5 8.2 ± 2.4
# 9.9 ± 2.7
# 7.9 ± 1.9
#
HPhobRep 16.4 ± 0.7 10.6 ± 0.5
# 12.2 ± 1.3 10.4 ± 1.5*
,#
HPhobPost 13.2 ± 1.1 7.6 ± 1.0
# 9.7 ± 1.3 7.9 ± 1.1
#
HPhobPre\10 14.6 ± 1.6 7.4 ± 1.2
# 11.9 ± 1.5
# 9.4 ± 1.3
#
HPhobPre[10 14.3 ± 0.9 7.3 ± 1.0
# 11.5 ± 1.1 8.6 ± 0.8
#
HPhobRep\30 17.1 ± 1.0 10.0 ± 2.1
# 11.8 ± 2.4
# 9.7 ± 2.2
#
HPhobRep[30 15.4 ± 1.1 9.1 ± 0.7
# 10.3 ± 0.9
# 8.0 ± 0.7
#
HR (beats/min)
Ctr 320 ± 15 291 ± 24 249 ± 23 230 ± 24
HPhilPre 299 ± 13 265 ± 27 257 ± 16 266 ± 16
HPhobPre 306 ± 11 283 ± 15 299 ± 12 265 ± 7
HPhobRep 330 ± 13 312 ± 5 315 ± 11 304 ± 9
HPhobPost 329 ± 26 339 ± 18 334 ± 18 328 ± 17*
HPhobPre\10 294 ± 10 264 ± 13 287 ± 15 269 ± 10
HPhobPre[10 298 ± 11 274 ± 6 274 ± 8 287 ± 10
HPhobRep\30 303 ± 10 272 ± 6 255 ± 28 253 ± 28
HPhobRep[30 290 ± 15 273 ± 14 241 ± 19 234 ± 18
Values represent mean ± SEM
Ctr ischemia–reperfusion controls; IPC ischemic preconditioning, 39
5 min; EffPre/HPhobPre 10 min efﬂuent administration prior to ischemia;
EffRep/HPhobRep 10 min efﬂuent administration at reperfusion; IPost
ischemic postconditioning, 39 30 s; EffPost/HPhobPost postconditioning
mimetic, 39 30 s; WI 10 min Wortmannin (1 lM); SH-6 10 min SH-6
(10 lM) at reperfusion. HPhil efﬂuent not bound to C18 column; HPhob
total efﬂuent eluted from C18 column;\or[10 or 30 kDa total hydro-
phobic fraction further separated by size exclusion column
* P\0.05 versus Ctr,
# P\0.05 vs. Stab
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123cell surface receptors initiating the IPC response (reviewed
in [7]). Being released into the circulation, the triggers have
also the potential to protect cells not directly subjected to
IPC [26], which could at least in part explain the phe-
nomenon of remote preconditioning (RIPC), in which
preconditioning of non-cardiac tissue such as skeletal
muscle [24] and kidney [33] will protect the heart from
subsequent ischemic events. The mechanisms behind RIPC
are believed to be shared with IPC and IPost [10], and
include the release of cardioprotective autocoids such as
adenosine [3], nitric oxide [29], activation of innate
immunity [36], activation of RISK signaling [9], and the
inhibition of the mitochondrial permeability transition pore
(mPTP) [13]. Recently, RIPC was also shown to work via
unidentiﬁed neurological or humoral pathways [19].
However, emerging evidences suggest that adenosine and
other small molecules involved in IPC protection might not
be responsible for the protective capabilities of the IPC
efﬂuent. Dickson et al. [5] compared adenosine levels in
coronary efﬂuent from preconditioned and control hearts,
and found no difference in mean adenosine concentrations.
They also failed to ﬁnd a relationship between adenosine
concentration and infarct size [5]. Using a 3.5 kDa dialysis
membrane, Serejo et al. [28] excluded low molecular
weight molecules (adenosine 267.24 Da, opioids
500–800 Da, and bradykinin 1,060.22 Da) without losing
the protective effect. Our study conﬁrms that the IPC
efﬂuent must contain cytoprotective substances larger than
3.5 kDa as the hydrophobic fraction[10 kDa resulted in
protection similar to the total hydrophobic and low
molecular fractions. Furthermore, our results also suggest
that smaller size molecules might not be necessary in
evoking the cytoprotective response, since the hydrophobic
fraction[10 kDa offered a reduction in infarct size
comparable to the total hydrophobic fraction.
Activation of RISK signaling during reperfusion unites
IPC, IPost and other agents that facilitate cardioprotection
when offered either prior to ischemia or at reperfusion [10],
and prolonging RISK activation by phosphatase inhibition
during reperfusion also offers cytoprotection [8]. Of note,
studies have questioned the importance of RISK in car-
dioprotection by IPost [27, 30] and in gentle reperfusion
[23]. However, Akt is an important mediator of RISK
signaling, and inhibition of the up-stream PI3-kinase with
either Wortmannin or LY 294002 reduced Akt phosphory-
lation and abolished IPC-mediated protection [21, 32]. We
have previously demonstrated that pharmacologically
induced phosphorylation of PI3K/Akt in the ﬁrst few min of
reperfusion after a sustained ischemic insult is cardiopro-
tective [14]. In the present study, we demonstrate that acti-
vation of Akt-dependent pro-survival signaling at
reperfusion is required for the pre-ischemic IPC efﬂuent-
induced protection. Inhibiting PI3K/Akt-signaling at the
onset of reperfusion in hearts pretreated with IPC efﬂuent
completelyabolishedtheprotection(Fig. 5).ThisPI3K/Akt-
dependent cytoprotection offered by pre-ischemic efﬂuent
treatment was paralleled by a signiﬁcantly increase in Akt
phosphorylation both pre- and post-ischemia (Fig. 4).
Administration of the efﬂuent as a reperfusion therapy also
resulted in increased Akt-phosphorylation, and the protec-
tion was abolished by PI3K/Akt-signaling inhibition. Taken
together, our data indicate that factor(s) retaining cytopro-
tective properties in IPC efﬂuent are conveying cardiopro-
tection via activation of Akt-dependent signaling that can be
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Fig. 6 The effect of fractionating the IPC efﬂuent based on charge
and size with regard to myocardial infarct size. Pre- or post-ischemic
administration of the total hydrophobic fraction (HPhobPre, HPhobRep
and HPhobPost) and the fractions containing proteins \ or [10 kDa
(HPhobPre\10 and HPhobPre[10) and\30 kDa (HPhobRep\30)
signiﬁcantly reduced infarct size in non-preconditioned recipient
hearts as compared to hydrophilic efﬂuent (HPhil) and control (Ctr)
hearts. The hydrophobic fraction containing proteins [30 kDa
(HPhobRep\30) did not offer any cytoprotection. HPhil efﬂuent
not bound to C18 column; HPhob efﬂuent eluted from C18 column;
total entire hydrophobic fraction;\or[10/30 kDa total hydrophobic
fraction further separated by a size exclusion column. Bars represent
mean ± SEM. N C 5 in each group. *P\0.05 versus Ctr
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123modulated at reperfusion after a lethal ischemic insult. We
could not prove involvement of the SAFE pathway [18],
which is thought to interact with RISK signaling at
reperfusion, as the IPC efﬂuent failed to modulate the
status of STAT3 phosphorylation (results not shown). In
addition to activation of Akt, the IPC efﬂuent has previ-
ously been shown to lose its protective effect when co-
administered with the PKC inhibitor chelerythrine [28].
PKC has been implicated as an early mediator of pre-
conditioning [31], and may contribute to Akt phosphory-
lation at the time of reperfusion [25], and thereby inducing
cardioprotection which may include inhibition of mito-
chondrial permeability transition pore (mPTP) opening
[9].
In conclusion, efﬂuent collected during ischemic pre-
conditioning of ex vivo rat hearts protects untreated reci-
pient hearts from reperfusion-induced injury via a PI3K/
Akt-dependent pathway that can be modulated at ischemic
reperfusion. The IPC efﬂuent has the ability to offer
cytoprotection when administered as a stimulus of remote
postconditioning (RIPost) or as a reperfusion therapy. The
molecules responsible for the efﬂuents protective abilities
are below or close to 30 kDa and at least one of them are
larger than 10 kDa. Furthermore, our results demonstrate
that the efﬂuent or its mediator(s) has a strong cardiopro-
tective action implying a great potential as adjunct reper-
fusion therapy for patients with AMI.
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